Anti‐CD20 mAb maintenance therapy vs observation
Overall survival · people with chronic lymphocytic leukaemia
Anti‐CD20 mAb maintenance therapy showed no clear difference in overall survival compared with observation (moderate certainty).
1 finding from 1 review
- HR 0.94 [0.73, 1.2]3 studies · 1152 participantsModerate